Amedeo Tirandi

Amedeo Tirandi

Auto-generated profile, based on publicly available information

Amedeo Tirandi

Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland; Department of Internal Medicine, University of Genoa, Genoa, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
APAlberto Preda
Alberto Preda
Federico CarboneFederico Carbone
Federico Carbone
ATAmedeo Tirandi
Amedeo Tirandi
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
LLLuca Liberale
Luca Liberale
Obesity epidemic reached the dimensions of a real global health crisis with more than one billion people worldwide living with obesity. Multiple obesity-related mechanisms cause structural, functional, humoral, and hemodynamic alterations with cardiovascular (CV) deleterious effects. A correct assessment of the cardiovascular risk in people with obesity is critical for reducing mortality and preserving quality of life. The correct identification of the obesity status remains difficult as recent evidence suggest that different phenotypes of obesity exist, each one associated with different degrees of CV risk. Diagnosis of obesity cannot depend only on anthropometric parameters but should include a precise assessment of the metabolic status. Recently, the World Heart Federation and World Obesity Federation provided an action plan for management of obesity-related CV risk and mortality, stressing for the instauration of comprehensive structured programs encompassing multidisciplinary teams. In this review we aim at providing an updated summary regarding the different obesity phenotypes, their specific effects on CV risk and differences in clinical management.

23 December 2025 in European Heart Journal
Verified
Journal Article
Open access
SKSimon Kraler
Simon Kraler
LLLuca Liberale
Luca Liberale
ATAmedeo Tirandi
Amedeo Tirandi
MMMargherita Moriero
Margherita Moriero
YWYifan Wang
Yifan Wang
TLThomas F. Lüscher
Thomas F. Lüscher
Background and Aims: Patients with acute coronary syndromes (ACS) are at high ischaemic risk to which cholesterol, inflammation, and yet-to-be-identified pathways jointly contribute. The junctional protein associated with coronary artery disease (JCAD) drives incident cardiovascular events by acting on coagulation and fibrinolysis. This study aimed to assess whether JCAD serves as a novel marker of or target to address residual risk. Methods: In the discovery cohort (SPUM-ACS; n = 4787), ACS patients at residual lipid risk [RLR; on-statin LDL cholesterol (LDL-c) ≥70 mg/dL or ≥1.8 mmol/L], residual inflammatory risk [RIR; on-statin high-sensitivity C-reactive protein (hs-CRP) ≥2.0 mg/L], or both (RILR; on-statin LDL-c ≥70 mg/dL and hs-CRP ≥2.0 mg/L) were identified and compared with propensity-score matched controls. Contributions of hs-CRP, LDL-c and JCAD to recurrent major adverse cardiovascular events (MACE) were analysed. In an independent cohort (RISK-PPCI study; n = 496), effects of JCAD on endogenous coagulation and fibrinolysis were gauged, and JCAD–MACE associations were externally validated. Results: At 1 year, patients at RLR, RIR, or RILR were at higher MACE risk as compared to controls [hazard ratio (HR), 1.55, 95% confidence interval (CI) 1.08–2.23; HR 1.80, 95% CI 1.24–2.61; and HR 1.75, 95% CI 1.12–2.75, respectively]. In those at RLR, MACE risk rose with increasing hs-CRP and JCAD, respectively, in uni- (HR per log2 increase, 1.17, 95% CI 1.06–1.30; HR 1.29, 95% CI 1.03–1.62) and multivariable-adjusted models [adjusted (a)HR 1.16, 95% CI 1.03–1.30; aHR 1.27, 95% CI 1.01–1.60]. In those at RIR, MACE risk increased 1.28-fold per log2 increase in JCAD (HR 1.28, 95% CI 1.03–1.59), which prevailed in multivariable-adjusted models (aHR 1.31, 95% CI 1.04–1.65). Similarly, in patients at RILR, MACE risk increased almost linearly with increasing JCAD (HR 1.45, 95% CI 1.09–1.92), independently of potential confounders (aHR 1.47, 95% CI 1.11–1.97). Plasma levels of JCAD correlated positively with proxies of impaired endogenous fibrinolysis, with the JCAD–MACE association being similarly observed in the external validation cohort. Conclusions: Acute coronary syndrome patients at RLR, RIR, or both are at high ischaemic risk. By modulating coagulation and endogenous fibrinolysis, JCAD represents a promising candidate to address the high residual risk that persists in ACS patients receiving guideline-recommended care. ClinicalTrials.gov Identifiers: NCT01000701, NCT02562690

1 August 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
SMStefano Ministrini
Stefano Ministrini
LLLuca Liberale
Luca Liberale
YPYustina M. Puspitasari
Yustina M. Puspitasari
JHJiaying Han
Jiaying Han
KKKilian Kirmes
Kilian Kirmes
GCGiovanni Camici
Giovanni Camici
BACKGROUND: Recent clinical trials demonstrated a reduction in biomarkers of thrombosis and inflammation in patients with very high cardiovascular risk treated with the anti–IL-6 (interleukin 6) monoclonal antibody ziltivekimab. However, if and how direct IL-6 inhibition exerts antithrombotic effects remains unknown. This translational project aimed to investigate the effect of direct IL-6 inhibition on experimental arterial thrombus formation and its underlying cellular mechanisms. METHODS: Three-month-old C57BL/6J male and female mice received very low dose lipopolysaccharide for 4 weeks; in addition to lipopolysaccharide, during the fourth week, mice were randomized to receive either anti-mouse IL-6 monoclonal antibody 200 μg or IgG1 isotype control. Thrombosis of the right common carotid artery was induced by endothelial-targeted laser injury. Coagulation factors and platelet reactivity were assessed in treated mice and controls. Platelets were isolated from whole blood and their reactivity to different chemical stimuli was measured by fluorescence-activated cell sorting. Additionally, whole blood samples from patients with a history of percutaneous coronary intervention were incubated ex vivo with either ziltivekimab biosimilar or IgG1 isotype control. Platelet reactivity at rest and in response to diverse chemical stimuli was quantified by fluorescence-activated cell sorting. RESULTS: Mice with low-grade chronic inflammation treated with anti–IL-6 monoclonal antibody displayed significantly blunted thrombus formation, without any significant difference in coagulation factors. Ex vivo stimulation with Collagen-rP (collagen-related peptide) significantly activated platelets isolated from control mice but not those obtained from mice treated with anti–IL-6 monoclonal antibody. Similarly, platelet reactivity from patients with previous percutaneous coronary intervention fell significantly after ex vivo treatment with ziltivekimab biosimilar. CONCLUSIONS: Direct IL-6 inhibition blunts thrombus formation by reducing collagen-induced platelet activation. These findings offer a potential mechanistic explanation for the results observed in the RESCUE trial and support the rationale of the ongoing ZEUS trial (Ziltivekimab Cardiovascular Outcome Study).

28 August 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SMStefano Ministrini
Stefano Ministrini
ATAmedeo Tirandi
Amedeo Tirandi
Potential involvement of von Willebrand factor in the development of heart failure. Von Willebrand factor (vWF) is expressed by endothelial cells and inactivated by the plasma metalloproteinase ADAMTS13 (disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). The choline transmembrane transporter Slc44A2, expressed on neutrophils’ surface recognizes vWF and induces neutrophil extracellular traps extrusion (NETosis). In cardiomyocytes, NETosis induces mitochondrial dysfunction, thus worsening myocardial function. Progression of heart failure is associated with systemic inflammation, and this further induces the endothelial expression of vWF and the inhibition of ADAMTS13. Created with BioRender.com.

2 July 2023 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
ATAmedeo Tirandi
Amedeo Tirandi
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
LLLuca Liberale
Luca Liberale

16 July 2024 in European Journal of Internal Medicine
Verified
Journal Article
Open access
LLLuca Liberale
Luca Liberale
CTClaudia Torino
Claudia Torino
PPPatrizia Pizzini
Patrizia Pizzini
SMSabrina Mezzatesta
Sabrina Mezzatesta
GDGraziella D'ARrigo
Graziella D'ARrigo
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco
In patients with kidney failure (KF) undergoing dialysis, neutrophils are dysfunctionally activated. Such chronic activation does not correspond to increased protection against infections and is thought to cause direct vascular damage accounting for the higher incidence of cardiovascular (CV) events. We hypothesized that circulating levels of neutrophil degranulation products (i.e. myeloperoxidase (MPO) and resistin) can predict overall and CV-specific mortality in dialysis patients. MPO and resistin levels were assessed in plasma samples from n = 1182 dialysis patients who were followed-up for median 2.9 years (IQR: 1.7-4.2). Patients were 65 ± 14 (SD) years old and 36 % women. Median value of MPO and resistin were 78 ng/mL (IQR: 54 - 123) and 72 ng/mL (IQR: 46 - 110), respectively. MPO and resistin levels correlated with biomarkers of organ damage, nutritional status and inflammation. Both MPO and resistin levels predicted all-cause mortality even after adjustment for traditional risk factors and inflammation, nutritional and KF-related indexes (MPO, HRfor 1 ln unit increase: 1.26, 95 %CI 1.11 - 1.42, P < 0.001; Resistin, HRfor 1 ln unit increase: 1.25, 95 %CI 1.09 - 1.44, P = 0.001). Similarly, their predictive ability held true also for CV death (MPO, HRfor 1 ln unit increase: 1.19, 95 %CI 1.01 - 1.41, P = 0.04; Resistin, HRfor 1 ln unit increase: 1.29, 95 %CI 1.07 - 1.56, P = 0.007). Plasma levels of MPO and resistin correlate with prospective overall and CV-specific mortality risk in KF patients undergoing dialysis and might be useful prognostic tools. Mediators of inflammation may be potential target to improve survival of those patients.